Ceapro Dirección

Dirección controles de criterios 3/4

El CEO de Ceapro's es Gilles Gagnon , nombrado en Jan 2008, tiene una permanencia de 16.25 años. compensación anual total es CA$560.00K, compuesta por 85.7% salario y 14.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.9% de las acciones de la empresa, por valor de CA$357.36K. La antigüedad media del equipo directivo y de la junta directiva es de 8.9 años y 9 años, respectivamente.

Información clave

Gilles Gagnon

Chief Executive Officer (CEO)

CA$560.0k

Compensación total

Porcentaje del salario del CEO	85.7%
Permanencia del CEO	16.3yrs
Participación del CEO	1.9%
Permanencia media de la dirección	9yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Recent updates

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Nov 28

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gilles Gagnon en comparación con los beneficios de Ceapro?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-CA$5m
Sep 30 2023	n/a	n/a	-CA$3m
Jun 30 2023	n/a	n/a	-CA$759k
Mar 31 2023	n/a	n/a	CA$2m
Dec 31 2022	CA$560k	CA$480k	CA$4m
Sep 30 2022	n/a	n/a	CA$6m
Jun 30 2022	n/a	n/a	CA$6m
Mar 31 2022	n/a	n/a	CA$5m
Dec 31 2021	CA$560k	CA$480k	CA$3m
Sep 30 2021	n/a	n/a	CA$2m
Jun 30 2021	n/a	n/a	CA$844k
Mar 31 2021	n/a	n/a	CA$1m
Dec 31 2020	CA$507k	CA$480k	CA$2m
Sep 30 2020	n/a	n/a	CA$3m
Jun 30 2020	n/a	n/a	CA$2m
Mar 31 2020	n/a	n/a	CA$630k
Dec 31 2019	CA$518k	CA$480k	-CA$1m
Sep 30 2019	n/a	n/a	-CA$855k
Jun 30 2019	n/a	n/a	-CA$1m
Mar 31 2019	n/a	n/a	-CA$657k
Dec 31 2018	CA$555k	CA$480k	-CA$316k
Sep 30 2018	n/a	n/a	-CA$2m
Jun 30 2018	n/a	n/a	-CA$2m
Mar 31 2018	n/a	n/a	-CA$1m
Dec 31 2017	CA$1m	CA$480k	-CA$958k

Compensación vs. Mercado: La compensación total de Gilles($USD409.87K) está por encima de la media de empresas de tamaño similar en el mercado Canadian ($USD174.90K).

Compensación vs. Ingresos: La compensación de Gilles ha sido consistente con los resultados de la empresa en el último año.

CEO

Gilles Gagnon (69 yo)

16.3yrs

Permanencia

CA$560,000

Compensación

Mr. Gilles R. Gagnon, M.Sc. MBA, ICD D, serves as Independent Director of Aeterna Zentaris Inc. since January 1, 2020. He serves as the President of Spectrum Pharma Canada Inc. (Spectrum Canada).Mr. Gagno...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Gilles Gagnon	CEO, President & Director	16.3yrs	CA$560.00k	1.9% CA$ 379.7k
Stacy Prefontaine	CFO & Corporate Secretary	9yrs	CA$232.99k	0.042% CA$ 8.3k
Bernhard Seifried	Senior Director of Research & Technology	no data	sin datos	sin datos
Michel Regnier	Senior Vice President of Technical Operations	less than a year	sin datos	sin datos

9.0yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de CZO es experimentado (8.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Gilles Gagnon	CEO, President & Director	16.7yrs	CA$560.00k	1.9% CA$ 379.7k
Genevieve Foster	Independent Director	2.1yrs	CA$92.38k	sin datos
William Li	Independent Director	9.5yrs	CA$59.57k	0.13% CA$ 25.9k
Ronald Miller	Independent Chairman	2yrs	CA$96.06k	sin datos
Ulrich Kosciessa	Independent Director	9.1yrs	CA$57.79k	0.10% CA$ 20.0k

9.1yrs

Permanencia media

Junta con experiencia: La junta directiva de CZO se considera experimentada (9 años de antigüedad promedio).

Ceapro Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Recent updates

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Third quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.011 profit in 3Q 2022)

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Second quarter 2023 earnings released: CA$0.015 loss per share (vs CA$0.021 profit in 2Q 2022)

The Returns At Ceapro (CVE:CZO) Aren't Growing

Ceapro Inc. Announces Resignation of Glenn Rourke as A Director

First quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.026 profit in 1Q 2022)

Ceapro Inc. Presents Encouraging Results from Research Collaboration Study with McMaster University Evaluating PGX-Processed Yeast Beta Glucan for Interstitial Lung Diseases

Full year 2022 earnings released: EPS: CA$0.056 (vs CA$0.037 in FY 2021)

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2A Human Clinical Trial Assessing Avenanthramide Tablets

Third quarter 2022 earnings released: EPS: CA$0.011 (vs CA$0.011 in 3Q 2021)

Ceapro Inc. Launches Next Phase of Scale Up for Disruptive PGX Technology to Pursue Product Development for Nutraceutical and Pharmaceutical Markets

Returns At Ceapro (CVE:CZO) Are On The Way Up

Ceapro Inc. Announces Positive Data from Bioavailability Studies Evaluating CoQ10 Formulations Impregnated with PGX-Processed Carriers

Second quarter 2022 earnings released: EPS: CA$0.021 (vs CA$0.009 in 2Q 2021)

Ceapro Inc. Appoints Sigrun Watson as Chief Revenue Officer

Ceapro's (CVE:CZO) Returns Have Hit A Wall

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

High number of new directors

First quarter 2022 earnings released: EPS: CA$0.026 (vs CA$0.007 in 1Q 2021)

Insufficient new directors

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

Full year 2021 earnings released: EPS: CA$0.037 (vs CA$0.024 in FY 2020)

Ceapro Inc., Annual General Meeting, Jun 01, 2022

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro Appoints Ronnie Miller to its Board of Directors

Ceapro (CVE:CZO) Will Want To Turn Around Its Return Trends

Third quarter 2021 earnings released: EPS CA$0.011 (vs CA$0.002 in 3Q 2020)

Second quarter 2021 earnings released

Be Wary Of Ceapro (CVE:CZO) And Its Returns On Capital

Ceapro Inc. Announces Completion of Patient Enrollment in Clinical Study Evaluating Beta Glucan as A Cholesterol-Lowering Agent

Ceapro's (CVE:CZO) Robust Earnings Are Supported By Other Strong Factors

First quarter 2021 earnings released

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Full year 2020 earnings released

New 90-day low: CA$0.63

Will Ceapro (CVE:CZO) Multiply In Value Going Forward?

Is It Too Late To Consider Buying Ceapro Inc. (CVE:CZO)?

New 90-day high: CA$0.79

Estimating The Fair Value Of Ceapro Inc. (CVE:CZO)

Ceapro Inc. (CVE:CZO) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

New 90-day high - CA$0.84

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media